Epstein-Barr virus-associated lymphoma developed shortly after immunosuppressive treatment for ulcerative colitis.
Akamatsu
Takuji
T
Watanabe
Norihiko
N
Chiba
Tsutomu
T
D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D020031:Epstein-Barr Virus Infections / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000209:etiology* / Q000503:physiopathology; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index
D007166:Immunosuppressive Agents